WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Friday, November 16, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email

Huntington's Disease Treatment Market to 2023 - Focus on the $1.5 Billion Market with Breakdown of Key Players and Therapeutics
Friday, November 09, 2018

DUBLIN, Nov. 9, 2018 /PRNewswire/ --

The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023" report has been added to's offering.

The global huntington's disease treatment market size is expected to be valued at USD 1.5 billion by 2023, registering a CAGR of 38.2% during the forecast period.

The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.

Huntington's disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.

The pipeline for Huntington's disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation. The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma's antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.

Further key findings from the report suggest:

    --  Teva is projected to become the market leader, capturing more than 45%
        of the market in 2023, driven by Austedo's rapid uptake and improved
        efficacy profile compared to its competitors. Teva's Huntexil is
        expected to be the only new symptom-alleviating drug to be launched
        during the forecast period
    --  Raptor's RP103 is expected to face head-to-head competition from Prana
        Biotech's Phase II drug PBT2 to be the first disease modifying therapy
        to be launched in the market
    --  Currently, 23 products are under clinical investigation for Huntington's
        disease, out of which, one is in Phase II/III each, thirteen in Phase II
        trials, two in Phase Ib/IIa, six in pre-clinical trials, and one in
        discovery phase
    --  EU5 will remain the second largest market with more than 15% share in
        2023, driven by rising disease prevalence, novel drug launches, and
        increase in R&D activities
    --  Companies are now focusing on development of treatments that can be
        injected directly in the brain to directly inhibit the formation of
        mutant HTT protein, instead of targeting the mutant protein
    --  Drugs with novel targets in early-phase development include Stealth
        Biotherapeutics' SBT-20 (mitochondria-targeted cytoprotective peptide),
        Cellavita + Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo/
        Shire's mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene

Key Topics Covered:

Chapter 1 Research Methodology
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1. Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Molecular Biology and Genetics of Huntington Disease (HD)
3.1.2 Signs and Symptoms
3.1.3 Biomarkers
3.1.4 Current Prevalence and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Huntington's Disease Treatment Market Overview
4.1 Therapeutic Classes for HD
4.2 Market, by Treatment
4.3 Sales Performance, by Treatment (2017 - 2023)
4.3.1 Symptomatic Therapy
4.3.2 Disease - Modifying Therapy
4.4 Market, by Mode of Administration
4.5 Market Size and Forecast (2017 - 2023)
4.6 Market Size and Forecast, by Seven Major Markets (2017 - 2023)
4.7 Market Share Distribution, by Company (2017 - 2023)
4.8 Market Dynamics and Brand Strategies
4.9 Patent Expiry Analysis
4.10 Huntington's Disease Treatment Market: Drivers and Restraints
4.11 M&A, Deal Landscape (2013 - 2018 YTD)
4.12 Pricing and Reimbursement Scenario
4.13 Huntington's Disease Sector SWOT

Chapter 5 Huntington's Disease Treatment Market: Pipeline Intelligence
5.1 Pipeline Landscape
5.1.1 Leading Drugs in Development
5.2 Key R&D Trends
5.2.1 Gene Therapy Antisense Oligonucleotides (ASO) Gene Therapy with miRNAs mRNA Splicing (Splicing Interference) Zinc - Finger DNA Binding Protein (ZFP)
5.2.2 Stem Cell Therapy
5.2.3 Small Molecules
5.3 Pipeline Landscape
5.3.1 Late Stage Pipeline Drugs
5.4 Clinical Profiles of Disruptive Drugs
5.5 Global Pipeline Forecast

Chapter 6 Company Profiles
6.1 Valeant Pharmaceuticals
6.1.1 Company Overview
6.1.2 Product Portfolio - Xenazine (tetrabenazine)
6.1.3 Product Forecast Sales through 2023
6.2 Teva Pharmaceuticals
6.2.1 Company Overview
6.2.2 Product Portfolio - Austedo (deutetrabenazine)
6.2.3 Product Forecast Sales through 2023
6.2.4 Strategic Initiatives Key Company News Flow
6.2.5 Pipeline Analysis and Overview Catalysts and Event Calendar
6.2.6 SWOT
6.3 Ionis Pharmaceuticals
6.3.1 Company Overview
6.3.2 Product Portfolio - IONIS - HTTRx/ RG6042
6.3.3 Product Forecast Sales through 2023
6.3.4 Strategic Initiatives Key Company News Flow Catalysts & Events Calendar
6.3.5 SWOT
6.4 Wave Life Sciences
6.4.1 Company Overview
6.4.2 Product Portfolio - WVE - 120101 and WVE - 120102
6.4.3 Product Forecast Sales through 2023
6.4.4 Strategic Initiatives Key Company News Flow Catalysts & Events Calendar
6.4.5 SWOT
6.5 Horizon Pharma
6.5.1 Company Overview
6.5.2 Product Portfolio - Procysbi (RP103)
6.5.3 Product Forecast Sales through 2023
6.5.4 Strategic Initiatives Key Company News Flow
6.5.5 SWOT
6.6 Prana Biotech
6.6.1 Company Overview
6.6.2 Product Portfolio - PBT2
6.6.3 Product Forecast Sales through 2023
6.6.4 Strategic Initiatives Key Company News Flow
6.6.5 SWOT

Chapter 7 Market Outlook
7.1. What the Future Holds
7.2. The Winners and Losers
7.2.1. Winners
7.2.2. Losers
7.3. Emerging Companies/New Technology Platforms
7.3.1. Vaccinex
7.3.2. UniQure
7.3.3. Stealth BioTherapeutics
7.3.4. Azevan Pharmaceuticals
7.3.5. Voyager Therapeutics
7.3.6. Sangamo/ Shire
7.4. The Road Ahead

For more information about this report visit

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav Arcis Golf Properties Honored Among "Best" By Avid Golfer Magazine Cowboys Golf Club No. 1 Overall Golf Club In DFW Region for 17th Year in a Row | Nov 16, 2018
Nav 1787fp Named Top 10 Wealth Management Technology Solution Providers for 2018 by Banking CIO Outlook | Nov 16, 2018
Nav American IRA Discusses How to Understand UBTI in a Self-Directed IRA | Nov 16, 2018
Nav Media Place Partners Announces Record Agency Growth | Nov 16, 2018
Nav SINA Corporation to Report Third Quarter 2018 Financial Results on November 28, 2018 | Nov 16, 2018
Nav Cognizant to Webcast Investor Day Today | Nov 16, 2018
Nav There Are More Ways to Market a Business Than With Just Advertisements, Says Brandon Frere | Nov 16, 2018
Nav Digital Marketing Company, fishbat, Shares 4 Reasons Images Help to Increase Engagement | Nov 16, 2018
Nav Demandbase Included On Deloitte's 2018 Technology Fast 500(TM) Fastest Growing Company In North America | Nov 15, 2018
Nav The9 Limited to Hold Annual General Meeting on December 17, 2018 | Nov 15, 2018

Submit News | View More News View More News